Article

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis

2013-11-15

Abstract excerpt

Abstract The JAK1/2 dual kinase inhibitor INC424 (ruxolitinibª, Jakafi¨) has been recently approved for the treatment of intermediate or high-risk myelofibrosis (MF) and is in late-stage clinical trials for polycythemia vera (PV). Although JAK inhibitors have been shown to improve patient constitutional symptoms and reduce splenomegaly, JAK inhibitor monotherapy does not significantly reduce mutant allele burden i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cdd682de-993a-580b-bc79-466df12ee5d9
DOI: 10.1182/blood.v122.21.666.666

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In MyelofibrosisDOI 10.1182/blood.v122.21.666.666Read

Targeting hedgehog signaling in myelofibrosis and other hematologic malignanciesSemantic proximity Read

Novel therapies for myelofibrosis.Semantic proximity Read

Smoothened Inhibitor, PF-04449913 Inhibits the Development of Myelofibrosis in a JAK2V617F Transgenic Mouse Model by Reducing TGF-β and MAPK Signaling PathwaysSemantic proximity Read

Loss of <i>Ezh2</i> synergizes with <i>JAK2</i> -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosisSemantic proximity Read

Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression.Semantic proximity Read

Rationale for combination therapy in myelofibrosis.Semantic proximity Read

New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.Semantic proximity Read

Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapySemantic proximity Read

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasmSemantic proximity Read

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.Semantic proximity Read

Janus activated kinase inhibition in myelofibrosis.Semantic proximity Read

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPNSemantic proximity Read